AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.

AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

/PRNewswire/ -- SueWallSt announces that a securities class action has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) on behalf of investors who...

Aardvark Therapeutics Faces Investor Class Action

SAN DIEGO, CA – September 10, 2026 (STL.News) Aardvark Therapeutics, Inc. (NASDAQ: AARD) is facing a federal securities class action lawsuit alleging that investors were misled about the safety and development prospects of its lead drug candidate, ARD-101, before clinical setbacks sent the biotechnology company’s shares sharply lower. The litigation comes as several securities law […] This News Aardvark Therapeutics Faces Investor Class Action a…

Kaplan Fox & Kilsheimer LLP Reminds Investors of a Securities Class Action Against Taboola.com Ltd. (NASDAQ: TBLA) and Lead Plaintiff Deadline on October 20, 2026

Open the article to view the coverage from NewMediaWire